Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group - Schmiegel, W H; Reinacher-Schick, A; Freier, W (Journal of Clinical Oncology, 2007)
ASCO Annual Meeting Proceedings Part I 2007